Exclusive: After winning legal battle, former PhaseBio investor finds US buyer for its PhIII drug to reverse Brilinta
Having wrangled control of a blood thinner reversal agent, SFJ Pharma has found a buyer for the drug.
SERB Pharmaceuticals, a specialty pharma that vastly expanded its portfolio through several mergers in recent years, is picking up US rights to bentracimab, which is designed to reverse the anti-coagulating effects of AstraZeneca’s Brilinta (ticagrelor). PhaseBio originally licensed the drug from AstraZeneca’s former biologics arm MedImmune, and SFJ hopped aboard midway with development funding. But when PhaseBio sounded an alarm bell regarding the company’s finances, SFJ demanded rights to the drug — and won the legal battle earlier this year. In the process, PhaseBio also filed for Chapter 11 bankruptcy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.